研究業績（原著論文のみ）/ Publications(Original Articles only)

• 2022-2023
• 2020-2021
• 2018-2019

• 2016-2017
• 2015-2014
• 2013-2012
• 2011-2006

2013年度

A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors.
Okamoto W, Yoshino T, Takahashi T, Okamoto I, Ueda S, Tsuya A, Boku N, Nishio K, Fukuoka M, Yamamoto N, Nakagawa K. Cancer Chemother Pharmacol. 2013 Nov;72(5):1063-71. doi: 10.1007/s00280-013-2277-8. Epub 2013 Sep 18.

Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma.
Kawakami H, Okamoto I, Terao K, Sakai K, Suzuki M, Ueda S, Tanaka K, Kuwata K, Morita Y, Ono K, Nishio K, Nishimura Y, Doi K, Nakagawa K. Cancer Med. 2013 Dec;2(6):933-41. doi: 10.1002/cam4.151. Epub 2013 Oct 27.

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production.
Yosuke Togashi, Tokuzo Arao, Hiroaki Kato, Kazuko Matsumoto, Masato Terashima, Hidetoshi Hayashi, Marco A de Velasco, Yoshihiko Fujita1 Hideharu Kimura, Takushi Yasuda, Hitoshi Shiozaki, and Kazuto Nishio Oncotarget. 2013.5(10) 2961-73.

The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer.
Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, Develasco MA, Kimura H, Matsumoto K, Tanaka K, Okamoto I, Ito A, Yamada Y, Nakagawa K, Nishio K. Oncogene. 2015 Jan 8;34(2):199-208. doi: 10.1038/onc.2013.547. Epub 2013 Dec 23.

EGFR T790M Mutation as a Possible Target for Immunotherapy; Identification of HLA-A*0201-Restricted T Cell Epitopes Derived from the EGFR T790M Mutation.
Yamada T, Azuma K, Muta E, Kim J, Sugawara S, Zhang GL, Matsueda S, Kasama-Kawaguchi Y, Yamashita Y, Yamashita T, Nishio K, Itoh K, Hoshino T, Sasada T.PLOS ONE . 8(11). e78389. 2013.11

The novel VEGF receptor/MET-targeted kinase inhibitor, TAS-115, has marked in vivo anti-tumor properties and a favorable tolerability profile.
Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T, Suzuki T, Ito S, Hashimoto A, Suefuji T, Egami K, Kazuno H, Suda Y, Nishio K, Yonekura K. Mol Cancer Ther. 2013 Dec;12(12):2685-96. doi: 10.1158/1535-7163.MCT-13-0459.

Overexpression of heparan sulfate 6-O-sulfotransferase-2 in colorectal cancer.
Hatabe S, Kimura H, Arao T, Kato H, Hayashi H, Nagai T, Matsumoto K, Velasco MA, Fujita Y, Yamanouchi G, Fukushima M, Yamada Y, Ito A, Okuno K, Nishio K. Mol Clin Oncol. 2013 Sep;1(5):845-850. Epub 2013 Jul 23.

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
Nishio M, Horai T, Horiike A, Nokihara H, Yamamoto N, Takahashi T, Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T. Br J Cancer. 109(3): 538-44. 2013.

Influence of novel supramolecular substance, [2] rotaxane, on the caspase signaling pathway in melanoma and colon cancer cells in vitro.
Hara K, Beppu T, Kimura M, Fujita Y, Takata T, Nishio K, Ono N. J Pharmacol Sci. 22(2):153-7.2013.>

Detection of EGFR T790M mutation in plasma DNA from patients refractory to EGFR tyrosine kinase inhibitor.
Sakai K, Horiike A, Darryl I, Keita K, Fujita Y, Tanimoto A, Sakatani T, Saito R, Kaburaki K, Yanagitani N, Ohyanagi F, Nishio M, Nishio K. Cancer Sci. 104(9). 1198-204. 2013.9.

A microarray-based gene expression analysis to identify diagnostic biomarkers for unknown primary cancer.
Kurahashi I, Fujita Y, Arao T, Kurata T, Koh Y, Sakai K, Matsumoto K, Tanioka M, Takeda K, Takiguchi Y, Yamamoto N, Tsuya A, Matsubara N, Mukai H, Minami H, Chayahara N, Yamanaka Y, Miwa K, Takahashi S, Takahashi S, Nakagawa K, Nishio K. PLOS ONE. 8(5): e63249. 2013.

Slug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.
Tamura D, Arao T, Nagai T, Kaneda H, Aomatsu K, Fujita Y, Matsumoto K, De Velasco MA, Kato H, Hayashi H, Yoshida S, Kimura H, Maniwa Y, Nishio W, Sakai Y, Ohbayashi C, Kotani Y, Nishimura Y, Nishio K. Cancer Med. 2(2):144-54. 2013.

SOX4 is a direct target gene of FRA-2 and induces expression of HDAC8 in adult T-cell leukemia/lymphoma.
Higuchi T, Nakayama T, Arao T, Nishio K, Yoshie O. Blood. 121(18):3640-9. 2013.

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma.
Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, Nishio K. Int J Oncol. 42(4):1151-8. 2013.

Gene amplification of ribosomal protein s6 kinase-1 and -2 in gastric cancer.
Yoshida S, Matsumoto K, Arao T, Taniguchi H, Goto I, Hanafusa T, Nishio K, Yamada Y. Anticancer Res. 33(2):469-75. 2013.

MET amplification as a potential therapeutic target in gastric cancer.
Kawakami H, Okamoto I, Arao T, Okamoto W, Matsumoto K, Taniguchi H, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K, Yamada Y. Oncotarget. 4(1):9-17. 2013.

LUZ-Lung 4: A phase II traial of afatinib in patients with advanced, non-small cell lung cancer who progressed on prior treatment with erlotinib, gefitinib, or both.
Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Kobayashi K, Takeda K, Kiura K, Nishio K, Seki Y, Ebisawa R, Shahidi M, Yamamoto N. J Clin Oncol. 31(27). 3335-41. 2013.9.

Phase I trial of OTS11101, an anti-angiogenic vaccine targeting Vascular Endothelial Growth Factor Receptor 1 in solid tumor.
Hayashi H, Kurata T, Fujisaka Y, Kawakami H, Tanaka K, Okabe T, Takeda M, Satoh T, Yoshida K, Tsunoda T, Arao T, Nishio K, and Nakagawa K. Cancer Sci. 104(1):98-104. 2013.

FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Arao T, Ueshima K, Matsumoto K, Nagai T, Kimura H, Hagiwara S, Sakurai T, Haji S, Kanazawa A, Hidaka H, Iso Y, Kubota K, Shimada M, Utsunomiya T, Hirooka M, Hiasa Y, Toyoki Y, Hakamada K, Yasui K, Kumada T, Toyoda H, Sato S, Hisai H, Kuzuya T, Tsuchiya K, Izumi N, Arii S, Nishio K, Kudo M. Hepatology. 57(4):1407-15. 2013.

2012年度

An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles.
Uemura M, Suzuki T, Nishio K, Chikuma M, Komeda S. Mtallomics, 4: 686-92, 2012.

Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
Hayashi H, Okamoto I, Kimura H, Sakai K, Nishimura Y, Nishio K, Nakagawa K. Anticancer Res. 32(10):4533-7. 2012.

Clinical Phase I Study of Elpamotide, a Peptide Vaccine for VEGFR 2, in Patients with Advanced Solid Tumors.
Okamoto I, Arao T, Miyazaki M, Satoh T, Okamoto K, Tsunoda T, Nishio K, Nakagawa K. Cancer Sci. 103(12):2135-8. 2012.

Hypoxia Induces Gefitinib Resistance in Non-Small Cell Lung Cancer with Both Mutant and Wild-type EGFR.
Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K. Cancer Sci. 103(11):1946-54. 2013.

N-myc Downstream Regulated Gene 1 (NDRG1) Promotes Metastasis of Human Scirrhous Gastric Cancer Cells through Epithelial Mesenchymal Transition.
Ureshino H, Murakami Y, Watari K, Izumi H, Kawahara A, Kage M, Arao T, Nishio K, Yanagihara K, Kinoshita H, Kuwano M, Ono M. PLoS One. 2012;7(7):e41312. Epub 2012 Jul 23.

Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K. Clin Cancer Res. 18(22):6219-26. 2012.

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells.
Tabara K, Kanda R, Sonoda K, Kubo T, Murakami Y, Kawahara A, Azuma K, Abe H, Kage M, Yoshinaga A, Tahira T, Hayashi K, Arao T, Nishio K, Rosell R, Kuwano M, Ono M. PLoS One. 2012;7(7):e41017. Epub 2012 Jul 17.

Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.
Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T, Nishio K. J Thor Oncol.7(11):1640-4. 2012.

An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting.
Goto K, Satouchi M, Ishii G, Nishio K, Hagiwara K, Mitsudomi T, Whiteley J, Donald E, McCormack R, Todo T. Ann Oncol. 23(11):2914-9. 2012.

Clinical outcome for EML4-ALK-positive patients with advanced non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Takeda M, Okamoto I, Sakai K, Kawakami H, Nishio K, Nakagawa K. Ann Oncol. 23(11):2931-6. 2012.

A Novel Mass Spectrometry-Based Assay for Diagnosis of EML4-ALK-Positive Non-Small Cell Lung Cancer.
Sakai, K, Okamoto I, Takezawa K, Hirashima T, Kaneda H, Takeda M, Matsumoto K, Kimura H, Fujita Y, Nakagawa K, Arao T, Nishio K. J Thor Oncol. 7(5):913-8. 2012.

K. Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification.
Okamoto W, Okamoto I, Arao T, Kuwata K, Hatashita E, Yamaguchi H, Sakai K, Yanagihara K, Nishio K, Nakagawa K. Mol Cancer Ther. 11(7):1557-64, 2012.

EGRI and FOSB gene expressions in cancer stroma are independent prognostic indicators for epithelial ovarian cancer receiving standard therapy.
Kataoka F, Tsuda H, Arao T, Nishimura S, Tanaka H, Nomura H, Chiyoda T, Hirasawa A, Akahane T, Nishio H, Nishio K, Aoki D. Genes Chromosomes Cancer. 51(3):300-12, 2012.

An in vivo highly antitumor-active tetrazolato-bridged dinuclear platinum(ii) complex largely circumvents in vitro cisplatin resistance: two linkage isomers yield the same product upon reaction with 9-ethylguanine but exhibit different cytotoxic profiles.
Uemura M, Suzuki T, Nishio K, Chikuma M, Komeda S. Metallomics 4(7):686-92, 2012.[Epub ahead of print]

Loss of genomic DNA copy numbers in the p18, p16, p27 and RB loci in blastic plasmacytoid dendritic cell neoplasm.
Oiso N, Tatsumi Y, Arao T, Rai S, Kimura M, Nakamura S, Itoh T, Nishio K, Matsumura I, Kawada A. Eur J Dermatol. 22(3):22(3). 2012.

Expression changes in arrestin β1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.
Matsuoka H, Arao T, Makimura C, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Tanigawara Y, Yamanaka T, Tanaka K, Nishio K, Nakagawa K. Oncol Rep 27(5): 1393-9, 2012

Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.
Kaneda H, Okamoto I, Sakai K, Tanizaki J, Takeda M, Nishio K, Nakagawa K. Acta Oncol. 51(7):942-4. 2012.

Slug is upregulated during wound healing and regulates cellular phenotypes in corneal epithelial cells.
Aomatsu K, Arao T, Abe K, Kodama A, Sugioka K, Matsumoto K, Kudo K, Kimura H, Fujita Y, Hayashi H, Nagai T, Shimomura Y, Nishio K. Invest Ophthalmol Vis Sci. 53(2): 751-6. 2012

SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in fastrointestinal cancer.
Tanaka K, Arao T, Tamura D, Aomatsu K, Furuta K, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Kimura H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K. Plos One 7(1): e27922, 2012.

FGFR2 gene amplification and clinicopathological featuers in gastric cancer.
Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y. Br J Cancer. 106(4):727-32, 2012.

Combined effect of ALK and MEK inhibotors in EML4-ALK-positive non-small-cell lung cancer cells.
Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K. Br J Cancer. 106(4): 763-7, 2012.

Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.
Makimura C, Arao T, Matsumoto K, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Nishio K, Nakagawa K. Anticancer Res. 31(12): 4561-8, 2011.

Plasuma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.
Sakamoto H, Kimura H, Sekijima M, Matsumoto K, Arao T, Chikugo T, Yamada Y, Kitano M, Ito A, Takeyama Y, Kudo M, Nishio K. Jpn J Clin Oncol. 42(2):105-12, 2012.

Successful long-term treatment with pemetrexed of NSCLC associated with EML4-ALK and low thymidylate synthase expression.
Takeda M, Okamoto I, Sakai K, Tanaka K, Terashima M, Nishio K, Nakagawa K. Clin Lang Cancer. 13(2): 157-9, 2012.

Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.
Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D, Aomatsu K, Kudo K, Kaneda H, Fujita Y, Matsumoto K, Yamada Y, Yanagihara K, Sekijima M, Nishio K. Cancer Sci. 103(2): 221-7, 2012.

Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.
Fujita Y, Islam R, Kaneda H, Kudo K, Tamura D, Aomatsu K, Nagai T, Kimura H, Matsutmoto K, Velasco MA, Arao T, Okawara T, Nishio K. Invest New Drugs. 30(5):1878-86. 2012.

Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Goto K, Ichinose Y, Ohe Y, Yamamoto N, Negoro S, Nishio K, Itoh Y, Jiang H, Duffield E, McCormack R, Saijo N, Mok T, Fukuoka M. J Thorac Oncol. 7(1): 115-21, 2012.